company background image
BCYC

Bicycle Therapeutics NasdaqGS:BCYC Stock Report

Last Price

US$32.41

Market Cap

US$942.0m

7D

22.8%

1Y

-35.6%

Updated

05 Dec, 2022

Data

Company Financials +
BCYC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BCYC Stock Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.

Bicycle Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bicycle Therapeutics
Historical stock prices
Current Share PriceUS$32.41
52 Week HighUS$61.50
52 Week LowUS$12.08
Beta0.79
1 Month Change36.75%
3 Month Change28.10%
1 Year Change-35.63%
3 Year Change322.01%
5 Year Changen/a
Change since IPO170.08%

Recent News & Updates

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Recent updates

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Mar 08
Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Feb 23
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year

Jan 19
Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year

What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?

Dec 15
What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?

Shareholder Returns

BCYCUS BiotechsUS Market
7D22.8%4.2%1.5%
1Y-35.6%-7.4%-14.9%

Return vs Industry: BCYC underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: BCYC underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is BCYC's price volatile compared to industry and market?
BCYC volatility
BCYC Average Weekly Movement8.0%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: BCYC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: BCYC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009149Kevin Leehttps://www.bicycletherapeutics.com

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.

Bicycle Therapeutics plc Fundamentals Summary

How do Bicycle Therapeutics's earnings and revenue compare to its market cap?
BCYC fundamental statistics
Market CapUS$942.05m
Earnings (TTM)-US$100.78m
Revenue (TTM)US$15.05m

63.9x

P/S Ratio

-9.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCYC income statement (TTM)
RevenueUS$15.05m
Cost of RevenueUS$69.85m
Gross Profit-US$54.80m
Other ExpensesUS$45.98m
Earnings-US$100.78m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.39
Gross Margin-364.12%
Net Profit Margin-669.65%
Debt/Equity Ratio10.4%

How did BCYC perform over the long term?

See historical performance and comparison